SOURCE: Goldman Small Cap Research, Inc.

October 02, 2013 09:30 ET

Upcoming Q4 Events Bode Well for Nuvilex Shareholders

BALTIMORE, MD--(Marketwired - Oct 2, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the fourth quarter of the year is typically a good one for micro cap stocks due to seasonal and macro issues and this year should be no different. For Nuvilex, Inc. (OTCQB: NVLX) shareholders, the last 3 months of the year should be extra sweet. 

At present, the Russell 2000 Index is heavily weighted in the financial services, consumer discretionary, and technology industries, while health care is only the 5th greatest weight. Given that just on Monday S&P Capital downgraded the financial services sector weighting and the seasonality of consumer discretionary stocks declines in the early part of the year, we expect a major shift in industry weighting during Q4. As a result, investors should prepare for a sector rotation to the health care and specifically the biotech arena, this quarter. 

Separately, one of the most opportunistic of the major oncology-focused biotechs, Celgene Corp. just made a $10M investment in Acceleron Pharma, a cancer treatment developer. This latest move is one in a recent series made by big pharma into smaller firms and Nuvilex likely remains on the list of qualifying candidates going forward.

On the micro front, Nuvilex investors may also be rewarded by upcoming milestones such as the pending closing of the diabetes technology treatment rights acquisition which was originally announced in 3Q13. This deal should immediately boost the Firm's valuation, upon closing. Plus, investors can expect to receive progress reports regarding the Firm's advanced clinical trials initiatives such as the production of the live cancer-drug-activating cells that will form part of the treatment to be used in its pancreatic cancer studies and the GMP facility in which the actual encapsulation of those cells will take place. 

All in all, with seasonality, sector rotation, and key milestone news ahead, Nuvilex's stock appears to have the wind at its back, which is good news for shareholders.

This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit:

Contact Information